NCT01725802View on ClinicalTrials.gov

A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 16, 2012

Primary Completion Date

February 26, 2013

Study Completion Date

February 26, 2013

Conditions
Parkinson's Disease
Interventions
DRUG

Levodopa/carbidopa solution for SC administration

DRUG

Placebo

Trial Locations (1)

Unknown

Hadassah Medical Center, Jerusalem

Sponsors

Lead Sponsor

NeuroDerm Ltd.
All Listed Sponsors
lead

NeuroDerm Ltd.

INDUSTRY

NCT01725802 - A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients | Biotech Hunter | Biotech Hunter